Pharma doesn’t always “invent” new drugs. Sometimes it simply re-labels old molecules—and bills billions.
Here’s the uncomfortable truth behind a lot of modern drug pricing: the next blockbuster often isn’t a brand-new compound. It’s an old molecule wi…

Biopharma is entering a new kind of “cliff”—not just patent expiration, but the operational scramble that follows it.
When a drug loses exclusivity, the market doesn’t simply get cheaper. It gets faster. Competitors move quickly, payers renegotiate agg…

One-shot: How to pick the right drug patent for maximum term-extension value
Most patent strategy conversations start with the same question: How do we extend exclusivity?
But the better question is: Which extension path actually pays—and which one q…

Drug patent litigation isn’t just about molecules—it’s about the art of “designing around” the claims.
In pharma, the public narrative often focuses on active ingredients: the drug, the target, the mechanism. But in the courtroom and the boardroom, t…

Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Pharma has a $300 billion question it can’t afford to misread: Is it “patent term restoration” or “patent term adjustment”?
On paper, the two concepts sound like close cousins. In practice, they can mean the difference between a blockbuster’s launch …

Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the game.
Eurasia looks familiar on the surface—markets, regulators, patents, generics. But the rules of the road are different enough that a s…

Pharmaceutical patent strategy is often discussed like a binary choice: fight for every right, or accept the inevitable and move on.
But the real world is messier—and more expensive—than that.
In a recent piece from DrugPatentWatch, the “Cut, Keep, or …

Most “market access” teams are playing defense. The winners sell before the clock runs out.
In pharma, timing isn’t a detail—it’s the business model.
If you’re a commercial market access vendor (or you support one), the biggest strategic mistake is wai…